VENCLYXTO®▼in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.1
Starting treatment for AML with VENCLYXTO,
a BCL-2 inhibitor, in combination with AZACITIDINE1
VENCLYXTO®▼ (VENETOCLAX) FOR NEWLY-DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY1
Please refer to SmPC before prescribing
Prescribing information can be accessed by the Prescribing Information button on the left
UK-VNCAML-220096 | November 2022.
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle: ▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.